Chugai and Towa’s Edirol Receive the MHLW Approval for the Treatment of Osteoporosis
Shots:
- The MHLW has approved Edirol (0.5µg/0.75µg) for the treatment of osteoporosis. The approval was based on the results of a bioequivalence study of Edirol tablet vs soft capsule and the tablet in 49 healthy adult volunteers
- Towa will oversee marketing and provide guidance on the use of Edirol tablet while Chugai will be in charge of obtaining approval, manufacturing Edirol & supplying it to Towa. Edirol capsule is still marketed & explained by Chugai
- Edirol is rated grade A as an active vitamin D3 preparation in the efficacy assessment to validate the increase in bone mineral density & decrease in a vertebral fracture in the 2015 prevention of osteoporosis and clinical practice guidelines
Ref: Chugai| Image: Chugai
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
